Inactive Instrument

GLG Pharma S.A.

Equities

GLG

PLM100000014

Biotechnology & Medical Research

Apollo Capital LLC acquired additional 7.5% stake in GLG Pharma S.A.

April 03, 2017

Apollo Capital LLC acquired additional 7.5% stake in GLG Pharma S.A. (WSE:GLG) on April 3, 2017. Apollo Capital LLC completed the acquisition of additional 7.5% stake in GLG Pharma S.A. (WSE:GLG) on April 3, 2017.

Latest news about GLG Pharma S.A.

Apollo Capital LLC acquired additional 7.5% stake in GLG Pharma S.A.	17-04-03	CI
GLG Pharma S.A. announced a financing transaction	15-10-29	CI
Astoria Capital Spólka Akcyjna acquired an additional 20% stake in M10 Spólka Akcyjna.	15-10-01	CI
Astoria Capital Spólka Akcyjna acquired 37.88% stake in M10 Spólka Akcyjna.	15-07-01	CI

Chart GLG Pharma S.A.

Duration

Period

More charts

Company Profile

GLG Pharma SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the research and development of therapies based on small molecules and formulations, which inhibit dysfunctional Signal Transducer and Activators of Transcription (STAT3) signaling. STAT3 is a signaling protein, which optimizes the human cell growth. The Company develops projects related to cancer and kidney disease treatment, as well as other drug applications. Its pipeline includes STAT3 inhibitors that mainly aim at treatment of chronic lymphatic leukemia (CLL), polycystic kidney disease (PKD) and triple negative breast cancer (TNBC). The Company performs clinical trials in laboratories located in Poland and the United States.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs